AI Rewires Biopharma BD — From Data Grunt to Strategic Lever
At BIO-Europe Spring 2026, a cross-sector panel dissected how generative AI is restructuring the business development workflow — from...
BIO-Europe Spring 2026
Europe’s Biotech Execution Gap Demands Capital Reform and Regulatory Harmony
At BIO-Europe Spring 2026 in Lisbon, investors and pharma executives diagnosed Europe's biotech bottleneck not as a science deficit...
AI Rewires Drug Discovery’s Economics, Infrastructure, and Biology Itself
At BIO-Europe Spring 2026, leaders from Eli Lilly, Schrödinger, Boltz, Bioptimus, and Sofinnova Partners convened to diagnose how foundation...